Trials Sponsors Conditions Drugs Pricing

Conditions

Idiopathic Pulmonary Fibrosis

Outcome Measures

Primary Outcomes (1)

Change from baseline in FVC (mL) at Week 24

Interventions

SALBUTAMOL Type not reported

InspiriaType not reported

Placebo of Inspiria (AGMB-447)Type not reported

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Participant aged ≥40 years at the time of signing the ICF.
Diagnosis of IPF within 7 years prior to the screening visit, confirmed by centrally reviewed HRCT of the chest
Confirmed pulmonary function criteria at screening, as follows: a. FVC ≥45% predicted of normal, as determined by spirometry, b. FEV1/FVC >0.7 or lower limit or normal, as determined by spirometry, c. DLCO corrected for hemoglobin ≥25% predicted of normal.

Sponsors & Collaborators

Agomab Spain S.L.U.
Industrylead

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Study Sites (53)

CCAB Centro Clinico Academico Braga Associacao

Braga, 4710-243, Portugal

Rui Rolo+351253027249 rui.rolo@hb.min-saude.pt

Unidade Local De Saude De Loures-Odivelas EPE

Loures, 2674-514, Portugal

Raquel Rosa+351219847200 raquel.rosa@ulslod.min-saude.pt

Unidade Local de Saude do Algarve E.P.E.

Faro, 8000-386, Portugal

Vanda Areias+351289891100

Central Study Contacts

Clinical Operations

3233189170 clinicalstudies@agomab.com

Study Design

Study Type: interventional
Phase: phase 2

Study Record Dates

First Submitted

July 17, 2026

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2026-526404-71-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-31 06:58:12 UTC

Documents

D1_Protocol 2026-526404-71-00_Redacted

A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (53)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (53)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

You may not qualify if:

Locations